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Age-related macular degeneration (AMD) is the most common cause of blindness in
the Western world and is characterised in its latter stages by retinal cell death and
neovascularisation and earlier stages with the loss of parainflammatory homeostasis.
Patients with neovascular AMD (nAMD) are treated with frequent intraocular injec-
tions of anti-vascular endothelial growth factor (VEGF) therapies, which are not only
unpopular with patients but carry risks of sight-threatening complications. A minority
of patients are unresponsive with no alternative treatment available, and some
patients who respond initially eventually develop a tolerance to treatment. New ther-
apeutics with improved delivery methods and sustainability of clinical effects are
required, in particular for non-neovascular AMD (90% of cases and no current
approved treatments). There are age-related and disease-related changes that occur
which can affect ocular drug delivery. Here, we review the latest emerging therapies
for AMD, their delivery routes and implications for translating to clinical practice.
Abbreviations: AAV, adenovirus; AMD, age-related macular degeneration; Ang2, angiopoietin-2; Aβ, amyloid beta; BCVA, best-corrected visual acuity; bFGF, basic fibroblast growth factor; BRB,
blood–retinal barrier; CC, choroidal capillaries; CFB, complement factor B; CFD, complement factor D; CFH, complement factor H; CFI, complement factor I; CNTF, ciliary neurotrophic factor;
CNV, choroidal neovascularisation; CPP, cell penetrating peptide; CRP, complement regulatory protein; CSF1, colony stimulating factor 1; DARPins, designed ankyrin repeat protein; DM,
Descemet's membrane; ECT, encapsulated cell technology; FGF-2, fibroblast growth factor 2; GA, geographic atrophy; GCL, ganglion cell layer; HDL, high density lipoprotein; hESC, human
embryonic stem cells; hUTCs, human umbilical tissue-derived cells; IFN-α-2a, interferon α-2a; IFN-β, interferon-β; INL, inner nuclear layer; iPSCs, induced-pluripotent stem cells; MAC, membrane
attack complex; MC, Müller cells; nAMD, neovascular age-related macular degeneration; ONL, outer nuclear layer; PDS, port delivery system; PEDF, pigment epithelium-derived factor; PEG,
polyethylene glycol; PGF, placental growth factor; PLGA, poly lactic-co-glycolic acid; PR, photoreceptor; RBP4, retinal binding protein 4; ROS, reactive oxygen species; RPDS, ranibizumab port
delivery system; RPE, retinal pigment epithelium; SASP, senescence-associated secretory phenotype; SDD, subretinal drusenoid deposits; SDS, sustained delivery system; SP1, sphingolipid 1; TJ,
tight junctions; TSPO, translocator protein 18 kDa.
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1 | INTRODUCTION
Age-related macular degeneration (AMD) is the most common cause
of visual loss in the developed world with 196 million people
worldwide living with AMD, which is predicted to rise to 288 million
by 2040 (Wong et al., 2014). Pathology associated with AMD occurs
in the retina, a photosensitive membrane in the posterior segment of
the eye which is responsible for vision, and in the choroidal blood
vessels which supply nutrients and remove toxins to and from the
retinal tissue. The neural retina is embryonically derived from the
central nervous system (CNS) and therefore does not endogenously
regenerate if injured or diseased. Thus, vision loss associated with
retinal degeneration is irreversible.
AMD can be categorised into two forms: dry (non-vascular)
AMD and advanced neovascular AMD (nAMD) (Figure 1). In the
early stages of dry AMD there is chronic low-level inflammation,
build-up of drusen deposits in the subretinal space and irreversible
loss of retinal pigment epithelium (RPE) and photoreceptors in the
macula, and subsequent progressive loss of central vision. In the
late stages of dry AMD, RPE degeneration becomes confluent and
vision loss is worsened, which is described as geographic atrophy
(GA). Unfortunately, there are no treatments available for
preventing sight loss in dry AMD patients, despite those individuals
representing 90% of AMD cases. Patients are advised to partake in
a healthy lifestyle, avoid smoking and to take anti-oxidant supple-
ments. Restoration of immune homeostasis is one of the possible
targets for emerging therapies to prevent sight loss in dry AMD
patients. In approximately 10% of patients, AMD can progress to
the more aggressive nAMD, which is associated with rapid loss of
central vision and is characterised by abnormal choroidal blood
vessel growth into the macula, called choroidal neovascularisation
(CNV). These vessels are ‘leaky’ and there is excessive scar tissue.
Currently, nAMD patients are treated with long-term, regular intra-
vitreal injections of anti-vascular endothelial growth factor (VEGF)
therapies (e.g., bevacizumab and aflibercept), aimed to reduce
angiogenesis, oedema and stabilise vision loss. However, these
therapies do not restore lost vision. Unfortunately, the long-term
outcomes with anti-VEGF therapies are poor and two thirds of
patients experience significant vision loss and almost all patients
exhibit GA of the macula after 7 years (Rofagha et al., 2013; Xu
et al., 2015). Additionally, long-term repeated intravitreal injections
can lead to complications (uveitis, endophthalmitis, subconjunctival
haemorrhage, elevated intraocular pressure and retinal detachment;
Falavarjani & Nguyen, 2013), low adherence and high economic
and societal costs and therefore long-lasting or minimally invasive
alternatives are urgently needed for these patients.
Inflammatory responses to AMD are discussed in detail in other
review articles (Copland et al., 2018; Handa et al., 2019; Perez &
Caspi, 2015). Here, we will evaluate the latest therapies in develop-
ment and clinical trials for treating AMD and discuss the delivery
routes, with the overarching goal for clinical translation and patient
treatment.
1.1 | Important considerations for AMD drug
delivery
Many therapeutic agents are efficacious in attenuating disease
pathogenesis in pre-clinical models of disease but often display poor
clinical translation and fail in early human clinical trials. The most com-
mon route of delivery to the posterior segment of the eye is through
localised intravitreal injections, where the therapeutic agent is deliv-
ered directly to the vitreous, which is in direct contact with the gan-
glion cell layer of the retina. However, intravitreal injections can be
unpleasant for the patient and pose complication risks and often
require multiple doses for effective treatment, resulting in a higher
cumulative risk of complications. Immunotherapies can be delivered
systemically through oral tablets or intravenous infusions, but sys-
temic manipulation of the immune system can cause widespread side
effects including infections of the CNS and activation of latent infec-
tions (Bascones-Martinez et al., 2014) and should be approached with
caution. There is a huge unmet clinical need for sustained, less inva-
sive alternatives for ocular drug delivery, which could include topical
eye drop delivery, implantation of refillable slow-release implantable
devices or single injection gene therapy. Despite long-lasting treat-
ment with gene therapy, these therapies are expensive and perma-
nent and therefore the pathophysiology needs to be evident and
there needs to be high confidence that the therapeutic agent will treat
the disease without adverse effects. There are obstacles to overcome
when designing ocular delivery agents, including penetration of the
ocular barriers, clearance of ocular fluid, tear film dilution and toxicity.
Additionally, the delivery system needs to be biocompatible and
remain optically clear within the vitreous to avoid interference with
vision. Further, the expense of production and scale-up processes for
the therapeutic agents need to be considered and financially afford-
able for patients. Repurposing drugs which have approval for use in
other disease could be considerably cheaper than novel therapeutics.
Figure 2 shows the age-related and disease-related changes in the
eye which can affect drug delivery and biodistribution. Moreover,
there are evident differences in pre-clinical model eyes compared to
human eyes which will affect ocular drug delivery and will be dis-
cussed later in the review.
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F IGURE 1 Pathophysiology of dry AMD and nAMD. In the healthy eye there is parainflammation and intact blood–retinal barriers (BRB). Dry
(non-vascular) AMD involves low levels of chronic inflammation and the production of pathological lipid deposits called drusen and subretinal
drusenoid deposits (SDD). Dry AMD can progress with widespread loss of photoreceptor (PR) and retinal pigment epithelium (RPE) cells, which is
called geographic atrophy (GA). In a subset of patients (10%), dry AMD can progress into the more aggressive neovascular AMD (nAMD),
characterised by abnormal choroidal blood vessel growth breaching Bruch's membrane into the retina, called choroidal neovascularisation (CNV)
and imbalanced angiogenesis factors (pigment epithelium-derived factor, PEDF; and vascular endothelial growth factor, VEGF). However,
development AMD is not always a linear progression and nAMD may occur in the absence of dry AMD pathology and nAMD can progress into
GA. Abbreviations: IL, interleukins; ROS, reactive oxygen species
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1.2 | Ocular barriers
The eye has complex barriers to maintain its immune privilege and
prevent infection. These same barriers also pose difficulties for
delivering therapeutic agents to the posterior segment of the eye
(Figure 2). Non-invasive delivery by topical administration is a
favourable alternative to intravitreal injections, but penetration of
these ocular barriers remains a huge obstacle in the successful
development of new treatments. Topically administered therapeutic
agents can become diluted in the tear film and cleared through
conjunctival blood vessels. These compounds need to transverse
multiple corneal layers (epithelium, Bowman's membrane, stroma,
Descemet's membrane and endothelium) and there are tight junc-
tions between the corneal epithelium which prevents hydrophilic
molecules from penetrating the tissue. The stromal layer has highly
organised and intertwined collagen fibres with a narrow pore size
which prevents the penetration of larger molecules. Less than 5%
of topically delivered treatments reach the anterior segment and
considerably less reaches the retina. Additionally, there are drug
transporters within the iris-ciliary body which actively eliminate the
drug and reduce its bioavailability. The drug must then diffuse
through the vitreous and penetrate the multiple retinal layers
(ganglion cell layer, inner limiting membrane, inner nuclear layer,
outer nuclear layer and outer limiting membrane) to reach the RPE
F IGURE 2 Age-related and disease-related changes to the eye which affect ocular drug delivery and biodistribution. There are numerous
barriers for delivering drugs into the eye, including the tear film, cornea, sclera and the blood–retinal barrier (BRB). There are age-related changes
in the eye and changes caused by AMD (dry and nAMD) pathology (grey boxes) which can affect drug biodistribution and pharmacokinetics
(green boxes). Many elderly individuals have comorbidities including an artificial lens from cataract surgery which needs to be considered when
designing therapeutic agents. Ageing leads to thickening of the vitreous which can adhere to the lens, affecting biodistribution of drugs.
Additionally, there is a systemic age-related decline in the immune homeostasis and lower numbers of T and B lymphocytes. Changes specifically
associated with AMD pathology include retinal pigment epithelium (RPE) and photoreceptor (PR) degeneration in dry AMD, but as the outer BRB
breaks down there is potentially improved drug delivery of systemically administered therapeutic agents. In nAMD, there is abnormal blood vessel
growth which are ‘leaky’ and lead to oedema and retinal scarring, which may reduce drug biodistribution. Abbreviations: CC, choroidal capillaries;
DM, Descemet's membrane; E, endothelial cells; GCL, ganglion cell layer; HDL, high density lipoprotein; INL, inner nuclear layer; MC, Müller cells;
ONL, outer nuclear layer; P, pericyte; SDD, subretinal drusenoid deposits; TJ, tight junctions
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and the choroid at a therapeutic dose. The physical and
biochemical barriers in the eye are massive hurdles to overcome
but knowledge surrounding the features and interactions with drug
delivery agents aid their development and successful translation.
Therapeutic agents delivered systemically must pass through the
blood–retinal barrier (BRB). The outer BRB is formed from tight junc-
tions between RPE, fenestrated choroid endothelial cells and Bruch's
membrane and prevents invading pathogens, circulating cells and mol-
ecules from freely entering the retina as well as retinal antigens from
entering into the circulation and activating the adaptive immune
response. The inner BRB is composed of tight junctions between reti-
nal capillary endothelial cells and regulates the movement of mole-
cules into the inner retina. In normal tissue, the BRB is intact and
endogenous ‘alarmins’ are unlikely to be detected by circulating or
choroidal antigen presenting cells (APCs), but, in AMD the outer BRB
can become disrupted and leaky as the RPE degenerate, allowing anti-
gen movement and activation of the immune response. This barrier
breakdown may also potentially allow access of systemically delivered
therapeutic agents into the eye.
1.3 | Drug delivery to the ageing eye
AMD primarily affects the elderly population and aged eyes differ
vastly from the eyes of juvenile patients. There are also structural
and biochemical changes that occur in the aged human eye which
can affect drug biodistribution (Figure 2), including a thicker, more
fibrosis structure to the vitreous, associated with loss of hyaluronate
and collapse of collagen fibres, leading to attachment to the lens
and subsequent difficulty with drug biodistribution (Mains &
Wilson, 2013). Cataract surgery and lens replacement are common
for elderly individuals; which means that the physical and biochemical
properties of an artificial lens need to be considered when designing
therapeutic agents for AMD. Interestingly, the artificial lens could be
utilised as a slow-release drug reservoir (Gonzalez-Chomon
et al., 2011). In the cornea, there are fewer corneal endothelial cells
and decreased stromal cell density, but thicker cornea epithelial and
endothelial basement membranes (Gipson, 2013), thus, although
increased amounts of a therapeutic agent might penetrate the outer
endothelial layer, the thicker membranes may be more impermeable.
Furthermore, there is a small decrease of 2.5% every decade in
aqueous humour outflow and fewer trabecular meshwork cells
(Alvarado et al., 1981; Diestelhorst & Kriegistein, 1992), which could
affect drug clearance. Also, age-related thickening of Bruch's mem-
brane (Bird, 1992) could hinder the delivery of systemically delivered
therapeutics. With age, there is a general decline in the immune sys-
tem, which increases the susceptibility to infections. Inflammaging is
a term used to describe chronic, subclinical form of dysregulated
parainflammation which occurs with age and contributes to the path-
ogenesis of multiple age-related diseases, including AMD. In asymp-
tomatic ‘healthy’ individuals, there is a decrease in tear film stability,
less tear production and higher levels of inflammatory markers
(ICAM-1, IL-8 and MUC5AC) with age, demonstrating the persistent
asymptomatic inflammatory state of inflammaging in the eye
(Di Zazzo et al., 2019).
1.4 | The tissue microenvironment in eyes
with AMD
The tissue microenvironment can alter the efficacy of drug penetra-
tion and pharmacokinetics (Nia et al., 2019). For example, photorecep-
tor and RPE atrophy associated with dry AMD will result in fewer
cells and barrier breakdown and remaining cells may have reduced
function. This could reduce efficiency of gene therapy, where cells are
required to translate therapeutic proteins transfected with viral vec-
tors. RPE atrophy can lead to BRB breakdown and may improve deliv-
ery of larger molecules from systemic administration. In nAMD there
is excessive, abnormal choroidal angiogenesis, with leaky vessels and
could lead to localised elevated fluid pressure and oedema. There is
also extracellular matrix remodelling, fibrosis and scar formation which
may reduce drug diffusion and penetration into the tissue.
2 | EMERGING THERAPIES AND THEIR
DELIVERY FOR TREATING AMD
The delivery of treatments to the posterior segment are a priority in
ocular research and have been reviewed in detail elsewhere (Del Amo
et al., 2017). Here, we will focus on the delivery of therapies to the
retina and choroid for treating AMD.
2.1 | Systemic immunosuppression
Systemic immunosuppression dampens down the immune response
and treatments are often administered by intravenous infusion or sub-
cutaneous injection. Interestingly in a large retrospective cohort study,
systemic immunomodulatory therapies do not affect the risk of onset
or progression of AMD in chronic kidney disease patients (Sandhu
et al., 2018). These include the corticosteroid prednisone, anti-
metabolites such as methotrexate and azathioprine, calcineurin inhib-
itors cyclosporin and tacrolimus, mammalian target of rapamycin
(mTOR) inhibitors sirolimus and everolimus, and T cell co-stimulation
antagonist belatacept (Sandhu et al., 2018). However, the anti-
metabolite mycophenolate mofetil did demonstrate some protection
against the conversion of dry AMD to nAMD in patients over 70, most
likely through the downregulation of IL-1β by leukocytes and
microglia, which would theoretically decrease CNV. In contrast, the
study shows that everolimus might increase the risk of developing dry
AMD (Sandhu et al., 2018). Furthermore, in a Phase II trial
(NCT00304954) intravitreal injections of anti-VEGF therapy in combi-
nation with systemic immunosuppressive therapy (daclizumab or
sirolimus) reduced the quantity of anti-VEGF injections needed to
maintain stable visual acuity, with injections required per month
reduced from 0.73 to 0.42 with daclizumab and 0.67 to 0.34 with
THOMAS ET AL. 5
sirolimus after 6 months (Nussenblatt et al., 2010). Moreover,
Alkahest, Inc. is developing an orally administered inhibitor of eotaxin
(AKST4290), through blocking its binding to its G-protein coupled
receptor CCR3, which plays important roles in inflammation, immune
cell recruitment and neovascularisation. In the Phase II PHTHALO-
205 trial (NCT04331730), AKST4290 was administered orally twice
daily for 36 weeks, with loading doses of intravitreally injected
aflibercept, in newly diagnosed nAMD patients. Results are expected
in 2021. These studies indicate that some systemic immunosuppres-
sive agents may be able to prevent the progression of early to late
AMD and therefore could be a useful preventative or in combination
with anti-VEGF therapies to reduce injection frequency.
2.2 | Anti-angiogenic therapies
2.2.1 | Anti-VEGF therapies
Anti-VEGF therapies are the most common treatment for nAMD. In
1989, VEGF was first reported as an angiogenic mitogen (Leung
et al., 1989) (Keck et al., 1989) and was later shown to be elevated in
the hypoxic retina of non-human primates injured with ischemic laser
photocoagulation causing neovascularisation in the iris (Miller
et al., 1994). There is a clear role for VEGF in abnormal angiogenesis
in ocular disease with elevated levels of VEGF detected in the ocular
fluid of patients with active neovascular eye disease (Aiello
et al., 1994). Most approved therapies for nAMD target VEGF to pre-
vent abnormal angiogenesis, which prevents further blood vessel
growth and stabilises vision loss but does not restore lost vision or
restore immune dysregulation associated with AMD.
The first anti-VEGF therapy developed for nAMD was
pegaptanib (Macugen®, Eyetech Pharmaceuticals, Pfizer), a 28-base
RNA aptamer which selectively binds and neutralises VEGF-165 iso-
form (Gragoudas et al., 2004) and was FDA approved in 2004 for ocu-
lar neovascularisation (Gonzales & Group VISiONCT, 2005).
Pegaptanib has modifications of two 20 kDa polyethylene glycol
(PEG) moieties to increase its vitreal half-life and modifications to pre-
vent endonuclease and exonuclease degradation. Subsequently,
bevacizumab (Avastin®, Genentech, Roche), a full-length humanised
monoclonal antibody with two VEGF-A binding sites, was FDA
approved for intravenous anti-angiogenic glioblastoma cancer ther-
apy, showed efficacy in nAMD patients when delivered systemically
(Michels et al., 2005) and via intravitreal injection (Rosenfeld
et al., 2005). Later, ranibizumab (Lucentis ®) was developed, which is
a modified version of bevacizumab and is an antibody fragment which
binds and inhibits all identified VEGF isoforms, and was FDA
approved for nAMD in 2006 for delivery via intravitreal injections
(Rosenfeld et al., 2006). A further approved therapy targeting VEGF is
the cytokine trap, aflibercept (Regeneron Pharmaceuticals).
Aflibercept is a soluble fusion protein consisting of two extracellular
cytokine receptor domains (VEGF-R1 and VEGF-R2) fused to Fc por-
tion of human IgG1 and acts as a decoy receptor, sequestering VEGF
and preventing its receptor binding and downstream biological effects
(Holash et al., 2002).
Anti-VEGF therapies are the current standard of care for
preventing further vision loss in nAMD patients, although some
patients are unresponsive to anti-VEGF therapies and still experience
substantial vision loss. One third of nAMD patients displayed signifi-
cant vision loss after receiving 7 years of VEGF-A blockade therapy
and every patient displayed central retinal atrophy (Rofagha
et al., 2013). This is consistent with pre-clinical rodent studies, with
VEGF-A blockade causing cytotoxicity in the retina (Nishijima
et al., 2007), highlighting the urgent clinical need for alternatives to
intravitreal injected anti-VEGF therapies.
Current anti-VEGF therapies are biologics/proteins which require
preservation of the tertiary and quaternary structures for their func-
tionality and environmental factors including the temperature, pH and
proteolytic enzymes can affect their structural integrity and function.
The current therapies have short half-lives of between 5–8 days and
hence require regular injections to prevent sight loss. A new anti-
VEGF therapy, brolucizumab (Beovu®, RTH258, formerly ESBA1008),
is a humanised single-chain antibody fragment which inhibits VEGF-A
and is smaller (26 vs. 115 kDa for aflibercept and 48 kDa for
ranibizumab) and has a longer half-life than aflibercept and
ranibizumab, allowing for a higher dose and longer intervals between
treatments (Holz et al., 2016). Theoretically, injecting a high drug con-
centration will create a large gradient from the vitreous to the retina
and its lower molecular weight will support greater drug bio-
distribution. Thus, decreasing the number of injections required for
equivalent clinical outcomes. Two Phase III trials, HAWK and
HARRIER (NCT02307682, NCT02434328), showed non-inferiority of
brolucizumab compared to aflibercept up to 48 weeks with 3-monthly
injections and the reported adverse rates were similar (Dugel
et al., 2017, 2020; Dugel, Singh, et al., 2021). Beovu® (Brolucizumab,
Novartis) was FDA approved in October 2019 for nAMD treatment.
Another alternative therapeutic is abicipar pegol (AGN-150998,
Allergan plc/Molecular Partners), a designed ankyrin repeat protein
(DARPins; a class of binding proteins which can aid protein–protein
interactions) and specifically binds with high affinity to all soluble
isoforms of VEGF-A. It has improved pharmacokinetic properties com-
pared with current anti-VEGF treatments as it has a lower molecular
weight (34 vs. 48 kDa) (Souied et al., 2014), higher target binding
affinity (2 vs. 46 pM) and longer ocular half-life (≥13 vs. 7 days in the
aqueous humour) compared with ranibizumab (Campochiaro
et al., 2013; Krohne et al., 2012). In the Phase II REACH trial
(NCT01397409), AGN-150998 showed comparable visual acuity and
central retinal thickness up to 20 weeks when intravitreally injected at
baseline and 4 and 8 month time points, compared to monthly
ranibizumab intravitreal injections (Callanan et al., 2018; Souied
et al., 2014). However, it failed to gain FDA approval in 2020 due to
significant intraocular inflammation (8.9% to 15.4%) and unfavourable
risk–benefit ratio (Khurana et al., 2020; Kunimoto et al., 2020). These
smaller, longer lasting anti-VEGF biologics offer an exciting opportu-
nity to increase the timeframe between intravitreal injections.
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Topical therapies
Many currently approved anti-VEGF biologics are large peptides
which also makes them less able to cross the ocular tissue membranes
and makes non-invasive drug delivery by topical administration chal-
lenging. The development of an anti-VEGF therapy as a topical ther-
apy is a viable alternative to intravitreal injections. Cell-penetrating
peptides are a class of penetrating enhancing agents composed of a
chain of positively charged peptides and can aid cellular and tissue
penetration (Pescina et al., 2018). Pre-clinical studies successfully
delivered anti-VEGF therapy, bevacizumab, as a topical administration
to the retina and demonstrated equivalent efficacy to intravitreal
injection in a mouse laser-induced CNV model (de Cogan et al., 2017).
Acrizanib (LHA510; Alcon) is a low molecular weight VEGFR2 inhibi-
tor which was delivered as a topical formulation but failed to show
efficacy compared to anti-VEGF injections (Poor et al., 2018). More-
over, PAN-90806 is a VEGFR2 tyrosine kinase inhibitor (TKI) which is
in development as a topical eye drop and delivered via the trans-
scleral route to reach the retina and choroid. Initial Phase I/II trial
studies (PanOptica, Inc. NCT0347937) showed reversible punctate
keratopathy from off-target effects (PanOptica I, 2019), but the
formulation has since been improved. PAN-90806 Phase I/II trials
(PAN-01-102) showed safety and biological response in nAMD
patients as a monotherapy, with 51% of patients on the study
receiving only PAN-90806 eye drops with no rescue anti-VEGF
injections (PanOptica I, 2019).
Sunitinib malate (GB-102) is a TKI which blocks signalling through
pan VEGF receptors and has completed Phase I/IIa trials. It is cur-
rently in the Phase IIb ALTISSIMO trial (NCT03953079, Graybug
Vision) to test the efficacy of GB-102 when intravitreally injected
every 6 months. Sunitinib microparticles, which are coated with
PLGA-PEG (to prevent pro-inflammatory effects), are in pre-clinical
development and offer an exciting sustained release delivery system.
These microparticles bind to melanin granules in the RPE and promote
a depot for sustained release. They also have a surface treatment to
promote self-aggregation in the vitreous to prevent interference with
vision (Bhatt et al., 2019; GraybugVision, 2019a, 2019b; Tsujinaka
et al., 2020; Ying et al., 2016). Furthermore, pazopanib is a multi-
targeted TKI which inhibits VEGFR 1, 2, 3 and platelet derived
growth factor (PDGF) signalling and has been developed as a topical
formulation, with a reduction in CNV size in pre-clinical models
(Takahashi et al., 2009; Yafai et al., 2011). In Phase II trials with 5 mg
ml-1 eye drops, applied 3 times daily, there was improved best-
corrected visual acuity (BCVA) in patients with sub-foveal CNV sec-
ondary to AMD (Danis et al., 2014). However, pazopanib failed to
meet its primary endpoints in a Phase IIb trial at Week 52, it was non-
inferior to ranibizumab and did not reduce the number of ranibizumab
injections by 50% (Csaky et al., 2015). Another therapeutic agent in
development is squalamine lactate, which inhibits angiogenesis
induced by VEGF, PDGF and basic fibroblast growth factor (bFGF) by
a novel intracellular mechanism and inhibits ocular neovascularisation
in pre-clinical models (Ciulla et al., 2003). Originally, squalamine lac-
tate was developed as an intravenous drug and demonstrated a bio-
logical effect, dose response and visual acuity benefit in Phase II trials,
but due to rapid clearance and impractical delivery it was not investi-
gated further. Ohr Pharmaceuticals launched a proprietary formula-
tion of 0.2% squalamine lactate eye drops (OHR-102), which have
improved trans-scleral permeability and increased retention at the tar-
get choroid tissue and have completed a Phase II IMPACT trial
(NCT01678963) in patients with all types of naïve neovascular
lesions. Patients were randomised to receive a ranibizumab intra-
vitreal injection at baseline followed by OHR-102 eye drops twice
daily or vehicle and received monthly intravitreal injections of
ranibizumab as needed. This trial demonstrated a trend towards better
visual acuity in patients receiving OHR-102 eye drops after 36 weeks
of treatment, particularly in a subgroup of patients who had classic
lesions and CNV less than 10 mm2. This patient subgroup was specifi-
cally recruited for Phase III trials (MAKO trial; NCT02727881), which
unfortunately failed to meet the primary endpoint and showed no
efficacy analysis.
Sustained release implants
An alternative method for sustained delivery is through surgical non-
biodegradable implants. These implants can be refilled in the clinic to
allow for long-term delivery of anti-VEGF or other therapeutic agents.
Genentech© are currently developing an implantable, reservoir based,
refillable implant called the Ranibizumab Port Delivery System (PDS)
(RPDS) for prolonged release to deliver ranibizumab for nAMD. This
system has entered Phase II clinical trials (LADDER trial;
NCT02510794), which has reported that sustained release of 100 mg
ml-1 of ranibizumab delivered via the RPDS induces similar visual acu-
ity outcomes to monthly ranibizumab intravitreal injections and has a
median refill time of 15 months (Campochiaro et al., 2019). However,
there were more adverse events associated with surgical implantation
of the device compared to intravitreal injections, with 179 of patients
(8.9%) with RPDS implantation developing serious adverse events
including vitreous haemorrhage. Two Phase III trials have launched,
ARCHWAY (NCT03677934) and PORTAL (NCT03683251) trials, to
compare monthly ranibizumab intravitreal injections with the RPDS
with refill every 24 weeks for 144 weeks. Preliminary results from the
ARCHWAY trial demonstrates 98.4% of patients with the RPDS main-
tain vision for 6 months without additional treatments and achieved
equivalent visual outcomes compared to monthly ranibizumab intra-
vitreal injections (Campochiaro et al., 2019). Another nAMD treat-
ment which has undefined mechanisms, RO-7250284 (Hoffmann-La
Roche; NCT04567303) has entered Phase I trials and is delivered via
intravitreal injections and the PDS, demonstrating the opportunity to
use this slow-release implantable device for other therapeutics. These
studies demonstrate the development of therapeutic agents with a
longer timeframe between treatments. This is likely to improve patient
compliance and reduce pressure on healthcare systems to administer
regular intravitreal injections, although the overall lifetime of the PDS
needs to be further explored.
Encapsulated cell technology
NT-503-3 is a sustained release device containing genetically
engineered RPE cells which produce anti-VEGF therapy and is
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delivered by an encapsulated cell technology (ECT) implant. Unfortu-
nately, a Phase II trial (Neurotech Pharmaceuticals; NCT02228304)
was terminated early due to a high rate of rescue events (Kiss, 2016).
The same ECT was used to delivery an implantation containing geneti-
cally modified human RPE cells producing sustained ciliary
neurotrophic factor (CNTF) for treating GA. NT-501 (Renexus®, NT-
501, Neurotech Pharmaceuticals; NCT00063765, NCT00447954),
produces continuous CNTF production for >5.5 years since implanta-
tion (Kauper et al., 2013). NT-501 has also been pre-clinically investi-
gated as a delivery agent for CR2-Fh (Annamalai et al., 2018).
Renexus® has been FDA approved for retinitis pigmentosa and macu-
lar telangiectasia and is in fast track for dry AMD.
Gene therapy
Gene therapy could offer an alternative for long-term delivery of anti-
VEGF treatments. A vector containing the gene which encodes for a
VEGF monoclonal antibody fragment can be injected as a one-time
subretinal treatment to provide a lifelong continuous supply to the
choroid and retina and reduce abnormal angiogenesis and CNV. RGX-
314, a NAV AAV8 vector encoding for soluble anti-VEGF protein is
currently in ongoing Phase II clinical trials for nAMD (Regenxbio Inc.
NCT03066258, AAVIATE trial NCT04514653) and is delivered into
the suprachoroidal space using a microinjector. Furthermore, ADVM-
022 (Adverum Biotechnologies Inc.), an AAV vector 7 m8-afibercept
in the OPTIC trial (NCT03748784) displayed long-term durability of
>1 year from a single intravitreal injection with no rescue injections
required in the higher dose 6  1011 vector genomes, but greatest
improvements from 2  1011 vector genomes group (n = 9) with
mean CRT change from baseline of 137.8 mm and mean BCVA gain
from baseline of +6.8 letters at 20 weeks (Khanani, Kiss, et al., 2020),
with the full study completion expected in 2022. An AAV2 vector
expressing an VEGF neutralising protein called SFLT01, which is a
novel fusion protein consisting of the VEGF binding domain of the
human VEGFR1/Flt-1 (hVEGF-R1) fused to the Fc portion of human
IgG through a polyglycine linker has shown a positive results when
delivered by subretinal injection in a transgenic mouse model of reti-
nal neovascularisation (trVEGF029 mice), with a reduction in fluores-
cein leakage from retinal vessels and improved retinal function (Lai
et al., 2009). A single subretinal injection of 1  1011 vector genomes
in Phase I and IIa trials (Adverum Biotechnologies Inc. NCT01494805)
showed no serious adverse effects or systemic safety concerns and
12 (57%) patients in the rAAV.sFLT-1 group maintained or improved
visual outcomes compared to only 4 (36%) in the control group
(Constable et al., 2016; Rakoczy et al., 2015). However, gene thera-
pies are very expensive and the treatment provides lifelong produc-
tion of protein which cannot be turned off. Therefore, it must be
shown that this therapy can improve the disease in the long-term
without adverse effects. As discussed earlier, the long-term delivery
of anti-VEGF therapies can induce poor outcomes, with two thirds of
patients experiencing significant vision loss and almost all patients
developing GA of the macular after 7 years (Rofagha et al., 2013; Xu
et al., 2015), indicating long-term delivery of anti-VEGF agents could
be detrimental.
Anti-VEGF and other pathways
There are newer therapeutic agents which target VEGF, in combina-
tion with other pathways shown to drive AMD pathology. For exam-
ple, IBI302 (Innovent Biologics Co. Ltd) is a novel bispecific decoy
receptor fusion protein designed with domains to inhibit both VEGF
and the complement cascade and are connected by the Fc region of
human immunoglobulin (Ren et al., 2016). IBI302 has shown anti-
angiogenic and anti-complement effects and positive pharmacokinetic
profiles in non-human primates (Ren et al., 2016) and is in ongoing
Phase I dose escalation trials for nAMD (NCT04370379; expected
June 2021). Furthermore, BI 836880 (Boehringer Ingelheim), a hum-
anised bispecific nanobody which targets VEGF and angiopoietin-2
(Ang2), a growth factor involved in angiogenesis, is in ongoing Phase I
trials (NCT03861234; expected October 2021). Hoffmann-La Roche
have also shown positive outcomes with faricimab (RO6867461,
RG7716; Hoffmann-La Roche), which simultaneously blocks VEGF
and Ang2. In the STAIRWAY Phase II trial (NCT03038880), 6 mg of
faricimab was intravitreally injected every 12 or 16 weeks which
resulted in the maintenance of initial vision and anatomical improve-
ments, comparable with monthly ranibizumab injections at 52 weeks
(Khanani, Patel, et al., 2020). These results suggest a role for simulta-
neous neutralisation of Ang2 and VEGF-A in providing sustained effi-
cacy through extended durability. However, nesvacumab-afibercept
(ONYX study), an aflibercept co-formulated with Ang2 antibody, failed
to meet the clinical endpoint at Week 36 in a Phase II trial
(Regeneron, 2017).
Treatments that are delivered by oral administration and target
VEGF are also in development. An oral angiogenesis inhibitor which
targets VEGF receptors, PDGFRs and colony stimulating factor 1
receptors (CSF1R) has shown positive results in a pre-clinical, laser-
induced CNV rat model, with high concentrations of CM082 reaching
the eye (173 ± 58 ng g-1) which is comparable to systemic plasma
concentrations (197 ± 73 ng ml-1), thus, demonstrating potentially
effective BRB penetration. The size of the laser-induced CNV was
also significantly reduced compared to vehicle. CM082 has entered
Phase II trials (X-82; Anew Pharma Inc.; NCT03710863) and will be
taken orally twice daily for 2 weeks followed by a 2-week interval, in
4-week cycles.
2.2.2 | Anti-PDGF agents
PDGF is an angiogenic factor which has been targeted for nAMD
therapies. HL-217 is a synthetic inhibitor of PDGF, which has shown
promising results at reducing CNV size in pre-clinical rodent studies
with topical application (Kim et al., 2015), has completed Phase I trials
(Hanlim Pharm. Co., Ltd. NCT03650608, NCT03648346) and has
entered Phase II trials (EudraCT number: 2019–000642-35).
Pegpleranib/Fovista (E10030; Ophthotech) is a PEGylated DNA
aptamer with selective anti-PDGFβ action and has completed success-
ful Phase I and II trials (NCT01089517) (Jaffe et al., 2016, 2017). In
Phase III trials (NCT01940900), 1.5 mg per eye of Fovista was
intravitreally injected in combination with 0.5 mg of ranibizumab and
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at 12 months showed no significant differences between the combi-
nation therapy and ranibizumab alone, leading to premature termina-
tion of the study (Dunn et al., 2017; Rosenfeld & Feuer, 2018).
Moreover, rinucumab-aflibercept, an aflibercept (anti-VEGF) co-
formulated with rinucumab (an anti-PDGF-Rβ antibody) failed in its
Phase II clinical trial (CAPELLA STUDY) due to no additional visual or
anatomical improvements with the combination therapy, compared
with aflibercept monotherapy at 3 months (Heier, Wykoff,
et al., 2020). Furthermore, regorafenib which inhibits VEGF-R 2/3
and PDGFR was terminated in a Phase IIa trial (DREAM study) due to
a loss of 2.4 EDRS letters at 12 weeks (Joussen et al., 2019). The lack
of therapeutic efficacy with anti-PDGF agents has been disappointing
and other avenues should be explored.
2.2.3 | Anti-FGF aptamers
Fibroblast growth factor 2 (FGF-2) inhibitors can block angiogene-
sis and retinal scar formation. An anti-FGF-2 aptamer (RBM-007)
inhibited FGF2-induced angiogenesis, laser-induced CNV and retinal
fibrosis (Matsuda et al., 2019) and pharmacokinetic studies in the
rabbit vitreous revealed high and relatively long-lasting profiles,
compared with approved anti-VEGF drugs (Matsuda et al., 2019).
RBM-007 is an FGF-2 aptamer in phase II TOFU trial (Ribomic
USA Inc. NCT04200248) and is administered as four monthly intra-
vitreal injections alone or in combination with aflibercept (expected
end date is June 2021). Furthermore, RemeGen Ltd have ongoing
Phase II clinical trials (NCT04270669) with intravitreal injections of
RC-28, a recombinant dual decoy receptor IgG1 Fc-fusion protein
that blocks both VEGF and FGF-2. These newly developed
therapeutic agents targeting FGF-2 could offer a vital alternative
for anti-VEGF unresponsive patients and also target retinal scar
formation.
2.2.4 | Amyloid-β targeted antibodies
Amyloid β (Aβ) aggregation in the brain are a fundamental characteris-
tic of Alzheimer's disease pathogenesis and has been implicated in the
development of AMD, due to their similarities with lipid depositions. Aβ
deposits might be associated with more advanced AMD, with an asso-
ciation of Aβ accumulating in retinal tissue with moderate to high
drusen levels (Anderson et al., 2004). Aβ is also present in nAMD and
may contribute to late stage nAMD pathogenesis. In cultured human
RPE cells, Aβ affected the angiogenesis-related factors, inducing VEGF
and decreasing pigment epithelium-derived factor (PEDF) protein
expression (Yoshida et al., 2005) and stimulating cellular senescence
and a pro-inflammatory microenvironment (Cao et al., 2013). Geneti-
cally modified mice with neprilysin deficiency, which induces increased
Aβ depositions, displayed AMD-like pathology including subretinal for-
mation of basal deposits and RPE degeneration, but, these mice did not
develop CNV up to the 27 month study endpoint (Yoshida et al., 2005),
suggesting Aβ depositionsmay induce early but not late AMD. Systemic
delivery of Aβ-therapy could be a potential viable route of administra-
tion for preventing vision loss in AMD patients as systemic Aβ-therapy
rescued visual defects in ApoE4-HFC transgenic mice (Ding
et al., 2008;, 2011). Despite positive results in pre-clinical studies,
Phase II clinical trials with anti-Aβ monoclonal antibodies from
Pfizer (RN6G, Pf-04382923; NCT01577381) and GlaxoSmithKline
(GSK933776; NCT01342926) were ineffective for dry AMD (Berger
et al., 2013). RN6Gwas administered as an intravenous 30-min infusion
(2.5–15 mg kg -1), but the study was terminated early due to an
organisational decision. GSK933776 was also delivered by intravenous
infusion at comparable doses (3–15 mg kg -1) but did not slow the rate
of GA enlargement compared to placebo and there were no clinically
meaningful differences in visual function over 18 months (Rosenfeld,
Berger, et al., 2018). A small peptide inhibitor which selectively targets
misfolded Aβ aggregations, GAL-101, and delivered as a topical formu-
lation 3 daily for 1 month reduced complement C3b in pre-clinical
studies (Hermann, 2019) and has successfully completed Phase I trials
for GA (RemeGen Ltd; NCT03777254). Together, these studies suggest
that Aβ depositions could play an important role in AMD pathogenesis,
but systemic delivery of anti-Aβmonoclonal antibodies have been inef-
fective at preventing disease progression in dry AMD, but topical appli-
cation of a selective small peptide inhibitor might be successful, and
may suggest that Aβ might not be the primary cause driving pathology
in AMD.
2.3 | Immunotherapies
Immunotherapies, where the immune response is stimulated or
suppressed to treat disease, are an exciting avenue for treating AMD
as they provide the promise to treat AMD pathology at an earlier
stage and halt disease progression through restoring immune homeo-
stasis, with downstream pathology prevented. Low-level inflammation
(parainflammation) is an important immunological mechanism for
maintaining tissue homeostasis and for monitoring tissue dysfunction.
However, if the optimal homeostatic threshold is not restored and
there are excessive parainflammatory responses, then this can result
in chronic inflammation and subsequent tissue dysfunction (Copland
et al., 2018). Immunomodulation through interleukins, interferons or
microglial-targeting therapies could be useful as therapeutics to
restore immune homeostasis and resolve chronic inflammation
in AMD.
2.3.1 | Interleukins
Interleukins are cytokines which are secreted from T cells, mono-
cytes, macrophages and endothelial cells and their main role is to
promote the growth and differentiation of haematopoietic cells and
T and B lymphocytes. Interleukins are strongly suggested to aid
the restoration of immune homeostasis in dry AMD and to prevent
the conversion to the more aggressive nAMD. These cytokines
may also present a suitable alternative for anti-VEGF unresponsive
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patients in nAMD. Rather than targeting anti-inflammatory mecha-
nisms, the promotion of inflammation may help tissue repair,
instead of hindering the repair process and leading to persistence
of disease.
Interleukin-18
The NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3)
inflammasome may be able to ‘sense’ drusen in human AMD donor
eyes and cleave pro IL-1β and IL-18 into their active forms to induce
an inflammatory response and pyroptosis (Doyle et al., 2012). As well
as raised IL-18 levels associated with AMD pathology, exogenous
mature interleukins may be protective and used an as immunotherapy.
In a laser-induced CNV mouse model, local and systemic delivery of
exogenous mature recombinant IL-18 effectively reduced CNV devel-
opment and was effective when intravitreally injected alone and as an
adjunct with anti-VEGF therapy (Doyle et al., 2014). Additionally, IL-
18 immunotherapy delivered as intravitreal injections demonstrated
tolerability and efficacy in non-human primates (Doyle, Lopez,
Celkova, et al., 2015). IL-18 can induce inflammasome activation and
RPE degeneration (Ijima et al., 2014) suggesting that IL-18 could
potentially exert detrimental rather than beneficial effects. Patients
with the auto inflammatory diseases, systemic juvenile idiopathic
arthritis and adult-onset Still's disease, have chronically elevated sys-
temic IL-18 but do not develop macular degeneration or CNV (Canna
et al., 2017), suggesting that long-term IL-18 immunotherapy would
not be detrimental to the retina. However, recombinant IL-18 did not
protect against CNV development and induced further RPE degenera-
tion (Hirano et al., 2014). These discrepant results are likely to be due
to the use of alternative recombinant mouse IL-18 which has a lower
bioactivity compared to the GlaxoSmithKline (GSK) generated
mouse IL-18 (SB-528775) which was used in the original studies
(Doyle et al., 2014; Doyle, Lopez, Celkova, et al., 2015; Doyle, Lopez,
Humphries, et al., 2015). SB-485232 has shown positive safety results
when injected systemically into 170 cancer patients (NTC00107718),
with no safety concerns or adverse visual effects reported (Robertson
et al., 2008). This suggests that immunotherapy with systemic IL-18
does not cause vision loss and is safe to use in humans. The anti-
angiogenic effects of IL-18 in nAMD are supported by further inde-
pendent studies (Marneros, 2013; Shen et al., 2014). Collectively,
these studies suggest that IL-18 could be a good adjunctive immuno-
therapy alongside anti-VEGF therapy to treat nAMD and will offer a
valuable alternative therapy for anti-VEGF unresponsive patients.
Interleukin-33
IL-33 has also been proposed to reduce neovascularisation in laser-
induction CNV mouse models (Theodoropoulou et al., 2017). IL-33 is
unique because it is active without caspase cleavage and does not
require inflammasome activation for secretion and bioactivity. It
behaves as an ‘alarmin’ and is released following cellular damage and
biomechanical overload (Lamkanfi & Dixit, 2009). It signals through a
heterodimeric receptor consisting of ST2 receptors and IL-1R acces-
sory protein, and the membrane form of ST2 is expressed on many
immune cells (Liew et al., 2016). In cell cultures, the recombinant form
of IL-33 (AA 112–270) reduces angiogenesis through the direct inhibi-
tion of human choroidal fibroblasts and choroidal endothelial cells,
both of which express a high level of ST2 receptors (Theodoropoulou
et al., 2017). In addition, in a laser-induced CNV mouse model delivery
of recombinant IL-33 through intravitreal injections reduced the lesion
size (Theodoropoulou et al., 2017), suggesting IL-33 could be a prom-
ising treatment for patients who are unresponsive to anti-VEGF thera-
pies. Furthermore, IL-33/ mice demonstrated elevated retinal
degeneration and gliosis following a retinal detachment injury com-
pared to controls, with sustained subretinal inflammation from infil-
trating macrophages (Augustine et al., 2019). Conversely, endogenous
IL-33 can promote an inflammatory response and recruit monocytes
in a phototoxic retinal degeneration model, which results in photore-
ceptor degeneration (Xi et al., 2016). These studies demonstrate the
opposing effects of endogenous and exogenous IL-33 and should be
considered in future therapeutic developments. IL-33 might also
be offered as a valuable therapeutic for restoring tissue homeostasis
in dry AMD patients. The delivery of exogenous recombinant IL-33
protein using intravitreal injections also demonstrated protection
against RPE degeneration and maintained metabolic retinal homeosta-
sis in CFH+/ aged mice fed on a high fat diet (Clare et al., 2020),
suggesting further evidence for IL-33 preventing AMD progression
and an exciting avenue.
Interleukin-10
IL-10 also has a role in AMD pathogenesis in mice, with increased
protein expression driving the activation of STAT3 signalling in
senescent macrophages and the promotion of vascular proliferation
and angiogenesis (Nakamura et al., 2015). Inhibition of the IL-10
receptors using a neutralising antibody against the IL-10-R1
reversed this disease phenotype, with a fivefold reduction in CNV
volume compared to control mice (Nakamura et al., 2015). Further-
more, intravitreal injection of STAT3-deficient macrophages into
the eyes of aged mice attenuated the CNV area (Nakamura
et al., 2015), suggesting that M2 macrophage specific targeting of
STAT3 signalling may be a novel therapy for treating nAMD. A pre-
treatment of low-dose lipopolysaccharide (LPS) delivered by intra-
peritoneal injection daily from 4 days before laser injury reduced
the CNV lesion size by 65% compared to control mice. This was
correlated with raised IL-10 protein in the serum and elevated IL-10
mRNA in peritoneal macrophages and peritoneal injection of anti-IL-
10 antibody reversed this protective effect (Matsumura
et al., 2012), indicating this pathology was IL-10-dependent and that
IL-10 could be delivered systemically as a therapeutic agent for
preventing neovascularisation in AMD.
2.3.2 | Interferon immunotherapy
Interferons are proteins produced in response to viral infections and
can boost the immune systems response. Interferon α-2a (IFN-α-2a)
is an anti-angiogenic molecule, which reduces abnormal angiogenesis
in retinal diseases in pre-clinical models. Nonetheless, clinical trials
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demonstrate that systemic delivery of IFN-α-2a or IFN-α-2b were not
advantageous in nAMD patients and may be more harmful than bene-
ficial (Lewis et al., 1993). This lack of effect could be explained by high
levels of neutralising antibody against IFN-α-2a in the serum of a pro-
portion of patients (Ross et al., 2002) and interferon treatment may
have a more localised effect if delivered into the eye. There are sev-
eral anti-angiogenic interventions available or in development, and it
is thus unlikely that further investigation into the use of interferons
for treating nAMD will be justified.
2.3.3 | Microglia targeting immunotherapies
In the healthy retina, microglia play an important role in immune sur-
veillance and preservation of tissue integrity. After an injury, they pro-
liferate and migrate to the damage site to phagocytose cell debris and
release neuromodulatory factors to promote tissue repair. Controlled
microglial activation for short periods can be protective, however, if
this becomes chronic and prolonged it can cause tissue damage.
Resident retinal microglia could be targeted therapeutically to prevent
neovascularisation and retinal degeneration (Akhtar-Schafer
et al., 2018).
Interferon-β (IFN-β), which can prevent activation of microglia,
has been proposed to have an immunomodulatory effect and reduces
laser-induced CNV in mice when delivered via systemic administration
(Luckoff et al., 2016). Furthermore, another potential therapeutic in
pre-clinical development are translocator protein 18 kDa (TSPO)
ligands. TSPO protein expression is highly induced, predominantly in
activated microglia. Synthetic TSPO ligands were used therapeutically
as immunoregulators to dampen microglial reactivity and reduce path-
ological outcomes. The TSPO ligand, XBD173, was systemically
administered in a mouse model of white light damage, which leads to
photoreceptor loss and outer nuclear layer thinning and showed
reduced microglial accumulation in the outer retina and significantly
reduced photoreceptor cell death (Scholz et al., 2015). Moreover, in a
laser-induced CNV mouse, microglial-specific TSPO-KO and treat-
ment with TSPO ligand XBD173 diminished mononuclear phagocyte
reactivity and neovascularisation (Wolf et al., 2020). These studies
highlight the potential of TSPO as a therapeutic agent for AMD and
its administration via systemic routes.
2.4 | Complement system-targeting therapies
The complement system is a subsection of the innate immune
response and is composed of soluble and surface proteins which
modulate the host defence against infection and antigen-specific
immune and inflammatory responses. Complement proteins
enhance the ability of antibodies and phagocytic cells to attack
pathogens, clear damaged cells and promote inflammation. The
complement system is chronically active at low levels in the eye
and complement components are present in the normal composi-
tion of tears, suggesting that it may act as an ocular primary
defence mechanism (Willcox et al., 1997). The dysregulation of the
complement pathway plays an important role in the pathogenesis
of AMD and can be targeted to restore immune homeostasis (Wu
& Sun, 2019).
2.4.1 | Complement components
Complement components and activation products, for example C3a,
C5a and the membrane attack complex (MAC), have been localised
to drusen deposits in post-mortem AMD eyes (Johnson et al., 2001).
Furthermore, the polymorphism rs2230199 (Arg80Gly) in the
complement protein C3 gene is associated with an elevated risk of
developing AMD (Yates et al., 2007). The generation of the MAC is
critical for the development of CNV, demonstrated by a lack of CNV
development from laser-induced injury in C3/ mice and mice
treated with anti-C6 treatments (Bora et al., 2005). Additionally, in
the absence of MAC formation, the release of angiogenic factors
including VEGF, TGF-β2 and β-FGF was inhibited (Bora et al., 2007).
This study highlights that an anti-C6 or anti-C3 antibody therapy
could be a potential therapeutic target for the treatment of nAMD.
NGM Biopharmaceuticals Inc. have developed a humanised IgG1
monoclonal antibody (NGM621) which potently inhibits C3 and is in
Phase II CATALINA trial for GA (NGM Biopharmaceuticals;
NCT04465955), with results expected in 2023. Patients with GA sec-
ondary to AMD will receive a single intravitreal injection every 4 or
8 weeks and the GA lesion area will be measured by fundus
autofluorescence at 48 weeks.
The complement activation products C3a and C5a could also be
potential therapeutic targets. C3a and C5a are present in drusen
deposits in human donor eyes and in the choroid of laser-induced
CNV mice (Nozaki et al., 2006), suggesting possible roles in both dry
AMD and nAMD. Zimura™ (also called avacincaptad pegol;
Ophthotech, INVERIC Bio Inc.) is an anti-C5 aptamer, which inhibits
C5 cleavage into C5a and C5b, thus decreasing MAC formation.
Zimura™ has completed a Phase II/III trial (GATHER1 study,
NCT02686658) in GA patients, with a significant reduction in GA
growth in eyes receiving intravitreal injections of avacincaptad pegol
(2 or 4 mg) over 12 months (Jaffe, Westby, et al., 2021) and has
entered Phase III trial to confirm efficacy (GATHER2 study,
NCT04435366). Zimura™ was also tested in Phase II trials in combina-
tion with Lucentis for nAMD patients, but despite promising results
Ophthotech have decided not to continue this pipeline for nAMD.
Moreover, Alexion Pharmaceuticals have completed Phase II trials in
2013 (COMPLETE trial, NCT00935883) with systemic administration
of eculizumab, a monoclonal antibody against C5a and C5b. Patients
with GA secondary to AMD received either 600 or 900 mg of the
therapeutic agent by intravenous infusion over 30 min each week for
4 weeks followed by 900 or 1200 mg every 2 weeks until Week 24.
Patients received a follow up to 6 months after the final treatment.
Unfortunately, systemic complement inhibition using eculizumab did
not reduce the growth rate of GA significantly, but was well tolerated
and there was some significant correlation between low-luminance
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deficit and the progression of GA over the 6 months (Yehoshua
et al., 2014).
Tesidolumab (LFG316) is a human immunoglobulin G1 (IgG1)
monoclonal antibody directed against the complement pathway
protein C5 and is in Phase II trials for GA (Novartis Pharmaceuti-
cals; NCT01527500) (Novartis, 2015). Novartis also have a
properdin/complement factor B (CFB) (positive regulator of the
alternative complement pathway) inhibitor which prevents the for-
mation of early (C3 cleavage) and late (C5 and the MAC) activation
products in the complement cascade, which is in Phase II trials for
GA as a monotherapy and also in combination with LFG-316
(Alcon Research, Novartis Institutes for Biomedical Research;
NCT02515942).
The formation of the MAC may be associated with decreased
complement factor H (CFH) and increased CFB in the RPE and cho-
roid in a laser-induced CNV mouse model (Bora et al., 2006). Sub lytic
MAC can have immunomodulatory roles, including induction of IL-6,
IL-8, CCL2 and production of angiogenic VEGF (Lakkaraju
et al., 2014). In addition to a potential protective anti-angiogenic role,
the inhibition of MAC formation could prevent RPE death and GA
associated with dry AMD. CD59 is a complement regulatory protein
(CRP) which inhibits MAC formation and CNV development. In
CD59a/ C57Bl/6 mice received laser-induced CNV and the CNV
lesion developed earlier in the disease process compared to wild-type
mice (Bora et al., 2007). Intraperitoneal or intravitreal injections of a
recombinant, soluble mouse CD59a-IgG2a fusion protein adminis-
tered 24 h before laser injury inhibited CNV development at 7 days
(Bora et al., 2007), by inhibiting the formation of MAC and reducing
downstream release of angiogenic factors such as VEGF, β-FGF and
TGF-β2 (Bora et al., 2007). Recombinant forms of CD59 could be used
as a potential therapy to treat nAMD and target later in the comple-
ment pathway and, thus, will not interfere with early complement acti-
vation which has vital roles in the host response to infection and
facilitating tissue healing. Gene therapy could be used to induce life-
long supply of the therapeutic agent and has shown promising results
at reducing RPE degeneration in vitro (Ramo et al., 2008) and attenu-
ating laser-induced CNV in mice (Cashman et al., 2011).
AAVCAGsCD59 (HMR59), a viral vector for the soluble CD59 has
completed a Phase I trial for GA and a trial for nAMD is ongoing
(Hemera Biosciences Inc. NCT03144999, NCT03585556). Janssen
Pharmaceuticals, Inc., has recently acquired the rights to HMR59 gene
therapy.
2.4.2 | Complement factors
Complement factors could also be targeted therapeutically. Allelic
variants in CFH are major risk factors in AMD development. For
example, a polymorphism of tyrosine to histidine at position 402 is
associated with a five to seven-fold increased risk of developing
AMD (Hageman et al., 2005). Aged (90 weeks old) CFH/ mice on
a high fat, cholesterol enriched diet spontaneously develop AMD-
like retinal phenotypes, such as photoreceptor dysfunction, C3
depositions and Bruch's membrane thinning (Coffey et al., 2007).
Gemini Therapeutics have initiated Phase I trial with a full-length
recombinant human CFH, GEM103, for treating dry AMD in
patients who have known CFH mutations (Gemini Therapeutics,
Inc.; NCT04246866).
Gene therapies are at the forefront of research and translation
into patients as they offer permanent, lifelong delivery of the thera-
peutic agent. However, they must be used with caution due to their
expense, permanent effect and, in the case of complement proteins,
an unproven mechanism from multiple failed trials. A novel specific
antisense oligonucleotide targeting the CFB gene (coding for
complement factor B) IONIS-FB-LRx (also known as ISI 696844; Ionis
Pharmaceuticals, Inc.) could be used to reduce the levels of circulating
CFB. IONIS-FB-LRx has shown promising clinical safety, pharmacoki-
netic and pharmacodynamic activity in a Phase I trial (ANZCTR regis-
tration number: ACTRN12616000335493) and is in ongoing Phase II
trials (GOLDEN study; NCT03815825) to determine if a subcutaneous
injection every 4 weeks will reduce the GA area growth over
12 months (Jaffe, Sahni, et al., 2020), with results expected in 2022.
Systemic targeting of complement should proceed with a level of cau-
tion as it has important roles in immune surveillance and inhibition
could induce broad, systemic side effects, including increased risk of
infection.
Moreover, Gyroscope Therapeutics is developing GT005, a novel
recombinant non-replicating AAV vector encoding for the human
complement factor I (CFI) protein, which is a negative regulator of the
alternative complement pathway. In pre-clinical models, GT005
showed dose-dependent CFI expression in the mouse eye following
subretinal injections, specifically in the RPE (Ellis et al., 2020) and led
to dose-dependent and significant reductions in CNV size in a mouse
CNV model. There were no adverse systemic effects found in mice or
non-human primates. These positive pre-clinical studies initiated a
Phase I/II clinical trials for GA secondary to dry AMD (FOCUS;
NCT03846193 and EXPLORE; NCT04437368), with no safety con-
cerns to date (Ellis et al., 2020). In the Phase I/II FOCUS trial, GT005
was delivered using the Orbit™ Sustained Delivery System (SDS),
which allows delivery to the subretinal space without the need for a
vitrectomy (removal of the vitreous) or retinotomy (a hole in the ret-
ina). This technology is also used to deliver cell therapies which will be
discussed later in the review.
There have been positive results with an antigen-binding frag-
ment of the humanised monoclonal antibody against complement
factor D (CFD), which selectively inhibits CFD and blocks the
alternate complement pathway, lampalizumab (also known as
RO5490249; Genentech, Hoffmann-La Roche). Lampalizumab is in
Phase II clinical trials (MAHALO; NCT01229215) for GA secondary
to AMD (Yaspan et al., 2017). The progression of GA lesion size
was 20% lower with monthly 10 mg lampalizumab compared to
sham, in particularly with carriers of CFI with 44% reduction in pro-
gression of GA area (Yaspan et al., 2017). This led to two Phase III
trials, the CHROMA and SPECTRI trials (NCT02247479,
NCT02247531), where patients received 10 mg of intravitreally
injected lampalizumab every 4 or 6 weeks, but there was no
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meaningful differences in the GA lesion area and thus the trials
were terminated early due to lack of efficacy at 12 months (Holz
et al., 2018). This was likely due to selective sub-optimal inhibition
of only the alternate complement pathway and minimal effect on
the classical and lectin pathways.
Lampalizumab, along with other complement-based treatments,
could be targeted too late in AMD pathogenesis to prevent GA
development. It is likely that complement activation precedes RPE
degeneration and atrophy of the choriocapillaris and that other
damaging biochemical pathways which are activated are indepen-
dent from the original complement over-activation by the time of
late therapeutic intervention in these trials. This suggests that
complement-targeting treatments may be more effective at an ear-
lier disease stage.
2.5 | Senotherapeutics
Senescence is a biological state whereby a cell permanently halts
cell division. These cells accumulate with age and secrete
senescence-associated secretory phenotype (SASP) proteins
(i.e., pro-inflammatory factors, pro-fibrotic factors, growth factors and
proteases) which affects the tissue microenvironment and can induce
senescence in neighbouring cells. The role of senescence in AMD is
emerging, with elevated expression of senescence markers p53 and
p21 and phospho-p38 MAPK levels in AMD (Lee et al., 2021). Sen-
otherapeutic agents are senolytics which selectively kill senescent
cells. UBX1967 and UBX1325 (Unity Biotechnology, Inc.) are sen-
olytic potent small molecule inhibitors of the Bcl-2 family, are in an
investigational new drug heading towards human trials (Unity Biotech-
nology I, n.d.). Although there are no therapies in trials for AMD cur-
rently, senotherapeutics offers a promising area for targeting AMD
pathophysiology from a new avenue (Lee et al., 2021).
2.6 | Cell therapies
There is a loss of functional RPE and photoreceptors in GA, which
are not endogenously replaced and can result in complete sight loss.
Cell therapy offers a viable opportunity to replace these RPE cells,
which are essential for the photoreceptor survival and function.
Importantly, the replacement cells must integrate into the neural
retina and provide functional as well as anatomical effects. Stem
cells which are differentiated into RPE cells are very effective but
are likely to be very expensive and might not be accessible for the
millions of AMD patients experiencing vision loss. Immunosuppres-
sive medicines are often taken to prevent rejection and another
potential limitation of cell therapy is uncontrolled cell multiplication
which can lead to tumour growth.
There are multiple cell therapies for dry AMD which have good
safety results and have entered Phase II trials. ASP-7317 is therapy
consisting of human RPE derived from human embryonic stem cells
(hESC) administered by subretinal injection (Astellas Pharma Inc.,
Astellas Institute for Regenerative Medicine; NCT03178149), with
primary completion date expected in 2027. Cells can also be grown
on membranes, such as the CRCB-RPE1 (California Project to Cure
Blindness RPE1) where 100,000 hESC-derived human RPE are
grown on a synthetic parylene membrane which replicates Bruch's
membrane, to be transplanted via subretinal injection in patients with
advanced dry AMD. This treatment showed feasibility and safety in
mini pigs (Koss et al., 2016) and Phase I/II trials (Regenerative Patch
Technologies, LLC; NCT02590692) excitingly demonstrate successful
hESC-hRPE and host photoreceptor integration and some improved
visual function in the short-term (12 months) (da Cruz et al., 2018;
Kashani et al., 2018). OpRegen® is another cell-based therapy of
hESC-derived hRPE and have showed long-term engraftment of the
RPE and continued progressive functional improvement, with 6 out of
7 patients treated with OpRegen® showing improved BCVA up to
12 months (Therapeutics LC, 2020). The therapy was delivered either
via the pars planar vitrectomy or using Orbit™ SDS (Gyroscope Thera-
peutics Limited), which allows a microinjection into the subretinal
space without damaging the eye or a need for a vitrectomy or ret-
inotomy. The Orbit™ SDS has recently received FDA 510(k) clearance
(August 2020).
Induced-pluripotent derived stem cells (iPSCs) differentiated into
RPE and grown on a biodegradable poly lactic-co-glycolic acid (PLGA)
scaffold showed promising results in rodent and pig models (Sharma
et al., 2019) and are in Phase I/IIa trials [National Eye Institute (NEI);
NCT04339764] with 12 patients with advanced GA and will be moni-
tored for 1 year. This therapy uses the patient's autologous blood cells
to avoid transplant rejection. In 2015, RIKEN suspended the first clini-
cal trials to use autologous iPSC transplants after treating a single
patient with AMD (Garber, 2015), in spite of successful pre-clinical
experiments (Kamao et al., 2014; Mandai, Fujii, et al., 2017) and an
intact transplanted iPSC-derived RPE cell sheet under the retina at
1 year after surgery and no alterations in BCVA in Phase I trial in a
patient with nAMD (UMIN-CTR number: UMIN000011929) (Mandai,
Watanabe, et al., 2017).
A further cell therapy used human umbilical tissue-derived cells
(hUTCs), which are not classed as a stem cell under the NIH defini-
tion as they do not grow indefinitely and do not spontaneously dif-
ferentiate when transplanted into other cell types. hUTCs can also
secrete neurotrophic factors which improve RPE function (Lund
et al., 2007). Subretinal delivery of these hUTCs, called palucorcel
(CNTO-2476) in Phase I/IIa trials (Janssen Research & Development,
LLC; NCT01226628) induced a high rate of retinal perforations
(13 patients) and retinal detachments (6 patients), out of 33 patients.
Although there was localisation of palucorcel in the subretinal space
and some improvement in visual acuity, the surgical approach must
be modified to prevent adverse effects (Ho et al., 2017). In Phase IIb
trials, a novel delivery system was used to deliver into the
suprachoroidal space, which was mostly well tolerated, with 16/21
patients experiencing mild adverse effects which resolved within
1 month and no major adverse effects (retinal detachment and perfo-
ration), although there was no apparent effect of treatment observed
with BCVA or GA area (Heier et al., 2020). Phase II trials were
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F IGURE 3 Ocular drug delivery routes and delivery technologies. Therapies that are in pre-clinical development (*) or clinical trials or are FDA
approved (†) are summarised according to their delivery route. Most therapies are delivered via intravitreal injection to provide localised delivery
to the posterior segment of the eye at high doses. Implantable devices can offer sustained release of treatments over a period of time with refill
options, and gene therapies are often intravitreal injected or subretinal to provide localised targeted delivery and translation of therapeutic
proteins. Abbreviations: Ang2, angiopoietin 2; AAV, associated adenovirus; CFD, complement factor D; CPP, cell-penetrating peptide; FGF,
fibroblast growth factor; IL, interleukin; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor
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withdrawn by company business decision (Janssen Pharmaceutical
K.K. NCT02895815).
2.7 | Other therapies
There are other therapies in clinical trials for AMD which will be
briefly mentioned. Clinical trials for dry AMD include ALK-001
(modified form of vitamin A D3) which is in Phase III trials as oral cap-
sules (Alkeus Pharmaceuticals, Inc. SAGA study, NCT03845582);
retinal binding protein 4 (RBP4) inhibitor LBS-008 (RBP4 Pty Ltd;
NCT03735810); and subcutaneously delivery of a mitochondrial-
targeted tetrapeptide which aims to reduce reactive oxygen species
(ROS) (elamipretide, Stealth BioTherapeutics Inc. ReCLAIM-2 study;
NCT03891875). Brimonidine tartrate (selective α2-adrenoreceptor
agonist) which is a commonly used glaucoma drug delivered via
intravitreal injection in a biodegradable polymer matrix is in early
phase trials for dry AMD. Emixustat hydrochloride (ACU-4429) is an
oral non-retinoid which inhibits RPE65, but has recently shown in
Phase II/III trials no significant reduction in growth of GA compared
to placebo over 2 years (Dugel et al., 2015; Rosenfeld, Dugel,
et al., 2018). Tonabersat (SB-220453; OcuNexus Therapeutics) is a
connexin-42 hemichannel blocker which is in early phase trials for dry
and nAMD (Mat Nor et al., 2020). RG-6147 (Genentech, Inc.
GALLEGO study, NCT03972709) and RG-7921 (Genentech, Inc.) are
in early phase trials for GA but have undefined mechanisms of action.
Topically administered MC-1101 is a vasoactive drug which increases
choroidal blood flow and has some anti-inflammatory and anti-oxidant
effects and is in Phase III trials for mild to moderate non-exudative
(dry) AMD (MacuCLEAR, Inc. NCT02127463).
Early phase therapies for nAMD include an anti-inflammatory
and anti-fibrotic therapy oral capsule OCX-063 (ANZCTR
F IGURE 4 Emerging therapies in clinical trials for dry and nAMD. Phase I, II and III clinical trials for nAMD (black text) and dry AMD (purple
text) are displayed in a wheel with type of treatment displayed. Clinical trials which were terminated or failed are indicated by a red cross.
Approved trials in clinic are also displayed
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number: ACTRN12619001607167); a monoclonal antibody against
sphingolipid 1 (SP1) (Resolute Pharma, NTC); PF-655, an siRNA
against mTOR (Quark Pharmaceuticals, Pfizer; MONET study,
NCT00713518); and AR-13503 SR which is a Rho kinase and pro-
tein kinase C inhibitor (Aerie Pharmaceuticals; NCT03835884).
Integrins are also a therapeutic target for AMD, with risuteganib
(an anti-integrin peptide) in Phase II trials for GA (Shaw
et al., 2020) and SF-0166 molecule integrin avβ3 antagonist in
Phase II trials as a topical solution for nAMD patients (SciFluor Life
Sciences, Inc. NCT02914639).
Therapies in pre-clinical development and clinical trials and their
delivery route are summarised in Figure 3. Phase I, II and III clinical tri-
als for nAMD and dry AMD and treatments which are clinically
approved are displayed in Figure 4. A selection of in clinical trials are
summarised in Table 1.
3 | CLINICAL TRANSLATION
The ultimate goal for drug discovery is clinical translation and treating
human disease. There are a range of therapeutic agents in develop-
ment paired with delivery technologies to overcome the physical and
biological barriers which hinder their delivery to the posterior seg-
ment of the eye. There are a few things to consider when designing
experiments to test novel therapeutics and delivery agents. Firstly,
the choice of animal model is important to ensure that the outcomes
are representative of what would happen in human pathology. The
pre-clinical animal models for AMD provide insight into translatabil-
ity, physiological outputs and toxicity, but there are anatomical differ-
ences between human and rodent eyes which need to be addressed,
particularly in respect to ocular drug delivery experiments. The
rodent lens occupies a large portion of the eyeball and contains less
vitreous compared to a human eye and this can produce differences
in drug biodistribution. Also, rodents do not have a macula in the ret-
ina, which is the primary structure affected by macular degeneration.
Secondly, many ocular drug delivery studies are performed in young
animals due to cost, ease of experiments and feasibility. However,
there are age-related changes in the structure and function of the
eye, meaning that successful drug delivery in a young eye might not
be replicated in an elderly eye. Thirdly, there are multiple models of
the disease pathologies in AMD, but often these are limited to
modelling specific aspects of the disease. For example, the most
commonly used model for studying nAMD, the laser-induced CNV
model, involves stimulating abnormal choroidal angiogenesis, but
does not induce this pathology through the initial cause but rather
through more severe induction of CNV, which is likely not to resem-
ble the process occurring in human AMD. Furthermore, there is no
good single model of dry AMD and current models replicate part of
the disease pathogenesis such as reduced autophagy, high fat diet,
CFH+/, SOD1/. Recently, there has been a research movement
towards using human tissue for studying pathogenesis and testing
novel therapeutics, with the organ-on-a-chip technology and human
iPSC-derived organoids at the forefront. These technologies offer a
vital improvement in pre-clinical model design. Finally, the pathway
to clinical translation is often extensive and it can take 15 years for
novel therapeutic agents or drug delivery technologies to reach the
clinic. The repurposing of FDA-approved therapies and delivery tech-
nologies will have faster translation for human use than novel, com-
plex, unapproved materials and should be given serious
consideration.
In addition, the endpoints of clinical trials are often late stage
pathology such as drusen and fluorescent angiography/CNV size.
There are no good biomarkers for detecting early AMD pathology,
which makes clinical translation and testing of new therapies chal-
lenging. Artificial intelligence (AI)-mediated detection of disease
could be used to support efficient endpoint identification for clini-
cal trials, hopefully sooner in the disease pathogenesis, which will
shorten necessary clinical trial length and accelerate clinical transla-
tion. The ability to detect pathology earlier could allow for inter-
vention and treatment before disease onset. Although studies are
in their early stages, AI could be used to predict AMD develop-
ment. A landmark study has developed algorithms to detect if and
when the second healthy eye in AMD patients develops CNV
pathology and requires therapeutic intervention with anti-VEGF
injections to prevent sight loss (Yim et al., 2020). Other studies
have detected AMD development through OCT scans and using
convolutional neural network (Hwang et al., 2019) and through
morphological changes in cones and rods (von der Emde
et al., 2019). These exciting advances in detecting AMD pathology
could revolutionise the translation of early AMD therapies into the
clinic.
4 | CONCLUSIONS
There are many emerging therapeutic agents in pre-clinical develop-
ment and clinical trials for AMD. These could provide a complemen-
tary therapy in combination with existing anti-VEGF therapies for
nAMD patients and provide a less invasive delivery route or longer
acting effect and thus reduce the number of intravitreal injections
required. There is still an urgent need for treatments to prevent sight
loss in non-neovascular AMD, with many promising treatments
emerging. There are many age and disease-related changes that
occur in the eye which may affect ocular drug delivery and must be
considered when designing therapeutics and pre-clinical studies.
Novel delivery technologies such as the sustained release using the
PDS and ECT could provide the opportunity for prolonged therapeu-
tic delivery and fewer hospital visits for regular intravitreal injections.
Gene therapies could offer the promise of a lifelong continuous sup-
ply of therapeutics, but with the high cost and a high percentage of
patients who receive long-term anti-VEGF therapies becoming non-
responsive and developing GA, there should be caution surrounding
long-term anti-VEGF gene therapy. Most therapies in early phase tri-
als for dry AMD have targeted the complement cascade, but there
has been a high failure rate due to lack of efficacy and after more
than a decade of attempts, other targets need to be explored.
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Cell-based therapies are emerging and many treatments have entered
Phase II trials, however, the expense of these treatments may not be
accessible for the wider population. Furthermore, immunotherapies
are an exciting avenue and target early dysregulation of the immune
response in AMD, offering earlier intervention and prevention of dis-
ease progression. There are many promising emerging therapies for
AMD and advances in ocular drug delivery technologies, which can
be combined to develop new treatments to preserve sight in our
ageing population.
4.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to Pharmacology
(http://www.guidetopharmacology.org), and are permanently archived
in the Concise Guide to Pharmacology 2019/20 (Alexander, Fabbro,
et al., 2019; Alexander, Kelly, et al., 2019).
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